SPRY — ARS Pharmaceuticals, Inc. stock price, charts and financials

QT29ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
5.46
+0.33+6.43%
OverviewShort InterestFilings
SPRYQT29ARS Pharmaceuticals, Inc.·NASDAQ
5.46+6.43%
News
Up 6.4% — ARS Pharmaceuticals Announces Conference Call and Webcast on August 13 Outlining its Updated Strategic Priorities and Reporting Second Quarter 2026 Financial Results (globenewswire.com).
Medium confidence
TA
Loading chart...
Signal & projected range
Short-squeeze setupHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
IOVA+6.14%$4.32FTRE-1.20%$18.94SLS+12.09%$11.22URGN+0.92%$38.59MESO+2.12%$14.47TSHA-1.37%$5.78TYRA+0.50%$32.04AUPH-2.08%$14.57
Snapshot
Index-P/E-EPS (ttm)-2.01Insider Own-Shs Outstand99.30MPerf Week-13.64%
Market Cap509.43MForward P/E-EPS next Y-0.93Insider Trans-0.06%Shs Float64.50MPerf Month-35.39%
Enterprise Value581.63MPEG0.03EPS next Q-Inst Own-Short Float35.15%Perf Quarter-37.89%
Income-198.01MP/S5.15EPS this Y14.15%Inst Trans-Short Ratio12.41Perf Half Y-49.80%
Sales98.99MP/B8.31EPS next Y46.11%ROA-68.84%Short Interest22.67MPerf YTD-55.97%
Book/sh-P/C-EPS next 5Y-ROE-153.61%52W High19.16 -71.50%Perf Year-71.31%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-85.03%52W Low5.44 0.39%Perf 3Y-26.71%
Dividend Est.-EV/EBITDA-Sales past 3/5Y337.95% 36.08%Gross Margin77.10%Volatility7.51% 6.48%Perf 5Y-84.29%
Dividend TTM-EV/Sales5.88EPS Y/Y TTM-2673.62%Oper. Margin-204.49%ATR (14)0.51Perf 10Y-
Dividend Ex-Date-Quick Ratio4.77Sales Y/Y TTM12.36%Profit Margin-200.00%RSI (14)21.83Recom2.50
Dividend Gr. 3/5Y-Current Ratio4.94EPS Q/Q-74.29%SMA20-24.90%Beta0.97Target Price25.50
Payout0.00%Debt/Eq1.57Sales Q/Q187.50%SMA50-36.97%Rel Volume1.02Prev Close5.13
Employees163LT Debt/Eq0.84EarningsAug 12SMA200-42.91%Avg Volume2.03MPrice5.46
IPO DateDec 04, 2020Option/ShortYes / YesEPS/Sales Surpr.-18.22% 2.17%Net Debt/EBITDA-0.38Volume2,080,449Change6.43%
Analyst Ratings
DateActionAnalystRatingTarget
Apr-09-26ReiteratedNorthland Securities
Mar-10-26ReiteratedLeerink PartnersOutperform$18
Nov-04-25ResumedRoth CapitalBuy
Sep-26-25ReiteratedRaymond JamesStrong Buy
Aug-19-24InitiatedCantor FitzgeraldOverweight
Aug-13-24UpgradeRaymond JamesOutperform → Strong Buy
Jul-25-24InitiatedRaymond JamesOutperform$18
Mar-05-24UpgradeLeerink PartnersMarket Perform → Outperform$14 → $18
Sep-20-23DowngradeWilliam BlairOutperform → Market Perform
Dec-13-22InitiatedLeerink Partners$14
Latest News
Today
Today07:30AM
ARS Pharmaceuticals Announces Conference Call and Webcast on August 13 Outlining its Updated Strategic Priorities and Reporting Second Quarter 2026 Financial Resultsglobenewswire.com
Jul-23-26
Jul-23-2610:00AM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRYprnewswire.com
Jul-21-26
Jul-21-2601:14PM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRYglobenewswire.com
Jul-15-26
Jul-15-2603:42PM
ARS Pharmaceuticals (SPRY) Appoints Donn Casale As The New CEOYahoo
Jul-14-26
Jul-14-2606:22PM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRYglobenewswire.com
Jul-09-26
Jul-09-2601:37PM
Can ARS Pharma's New CEO Unlock Neffy's Potential?Benzinga
Jul-07-26
Jul-07-2605:38PM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRYglobenewswire.com
04:30PM
ARS Pharmaceuticals Announces CEO Successionglobenewswire.com
Jul-06-26
Jul-06-2602:00PM
ARS Pharmaceuticals (SPRY) Securities Fraud Investigation - Levi & Korsinskyprnewswire.com
Jul-01-26
Jul-01-2610:07AM
SPRY Investor Alert: Levi & Korsinsky Investigates ARS Pharmaceuticals (SPRY) for Potential Securities Fraudbusinesswire.com
Jun-30-26
Jun-30-2604:45PM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRYglobenewswire.com
Jun-29-26
Jun-29-2602:00PM
ARS Pharmaceuticals Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of ARS Pharmaceuticals (SPRY)gurufocus.com
Jun-28-26
Jun-28-2612:00PM
SPRY Investors Have Opportunity to Join ARS Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firmgurufocus.com
Jun-26-26
Jun-26-2610:18AM
Apogee Enterprises Posts Strong Q1 Earnings, Joins ACADIA Pharmaceuticals, Crocs And Other Big Stocks Moving Higher On FridayBenzinga
Jun-25-26
Jun-25-2602:08PM
ARS Pharma: Strong Growth Meets A Coverage WallSeekingAlpha
Company

ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue10084890161800
Cost of Goods Sold Incl. D&A22202101701421
Gross Profit7664690-1654-2-1
Selling, General and Administrative Excl. Other261230047195412
Research and Development141320201820142215
Other Operating Expense40521-170-1400
Operating Income-202-179-3-68-36-190-24-18
Interest Expense2300000—0
Unusual Expense
—————————
Non-Operating Income (Expense)71111131-1-101
Net Income Before Taxes-198-1718-54-35-20-1-24-18
Income Taxes
000000000
Consolidated Net Income-198-1718-54-35-20-1-24-18
Net Income From Continuing Operations-198-1718-54-35-20-1-24-18
Net Income-198-1718-54-35-20-1-24-18
EPS (Recurring)-2.01-1.740.08-0.57-0.87-0.70-0.03-0.72-0.53
EPS (Basic, Before Extraordinaries)-2.01-1.740.08-0.57-0.87-0.70-0.03-0.72-0.53
EPS (Diluted)-2.01-1.740.08-0.57-0.87-0.70-0.03-0.72-0.53
EBITDA-193-1678-54-34-200-23-17
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio——135.08——————
Price To Sales Ratio5.4113.7311.50—341.2032.1990.11——
Gross Margin76.0076.1977.53—-1,600.0083.3322.22——
Operating Margin-202.00-213.10-3.37—-3,600.00-316.670.00——
Net Margin-198.00-203.578.99—-3,500.00-333.33-5.56——
Shares Outstanding999997954029353333
Market Capitalization5411,1531,0235213411931,622——
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$20.33$16.04$11.74$7.44$3.15● Close Price0.00M0.42M0.83M1.25M1.67MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Karas EricChief Commercial OfficerJun 12 '26Option Exercise1.5025,00037,50037,176Jun 12
Karas EricChief Commercial OfficerJun 12 '26Sale10.0025,000250,00012,176Jun 12
Fitzpatrick Alexander AChief Legal OfficerJun 12 '26Sale10.003,35533,55090,910Jun 12
Dorsey BrianChief Operating OfficerNov 13 '25Option Exercise0.6421,82813,97032,617Nov 14
Dorsey BrianChief Operating OfficerNov 13 '25Sale8.7121,828190,05010,789Nov 14
Chakma JustinChief Business OfficerNov 12 '25Option Exercise0.8430,00025,200166,380Nov 14
Chakma JustinChief Business OfficerNov 12 '25Sale8.87166,3801,476,1470Nov 14
Lowenthal Richard EPRESIDENT AND CEOAug 21 '25Sale14.4950,000724,3451,196,494Aug 22
Scott Kathleen D.Chief Financial OfficerAug 21 '25Option Exercise1.5012,50018,75022,542Aug 22
Scott Kathleen D.Chief Financial OfficerAug 21 '25Sale15.0012,500187,50010,042Aug 22
Tanimoto SarinaCHIEF MEDICAL OFFICERAug 20 '25Sale14.0937,656530,6261,247,447Aug 21
Tanimoto SarinaCHIEF MEDICAL OFFICERAug 19 '25Sale14.0312,344173,1301,285,103Aug 21
Karas EricChief Commercial OfficerJul 01 '25Option Exercise1.5015,00022,50025,315Jul 03
Karas EricChief Commercial OfficerJul 01 '25Sale16.9915,000254,86110,315Jul 03
Flynn James E10% OwnerJun 27 '25Sale18.46370,0746,831,5664,887,254Jul 01
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.